I reposted this article about
Boniva since I didn't have a subject line the first time.
Bloomberg News (9/26, Bennett) reports,
"Roche Holding AG (ROG)'s bone-strengthening drug Boniva [ibandronate]
works as well as radiotherapy at relieving pain associated with prostate cancer
that's spread to the bones," according to "a trial involving 470
patients," which found that "a single dose of Boniva given
intravenously was equivalent to a single dose of radiation for pain relief a
year after treatment." The study was announced at the European
Multidisciplinary Cancer Congress (EMCC) in Stockholm. Reuters (9/26, Kelland) explains that the drug
is a bisphosphonate.